CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement
Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common neoplasm of the lymphatic system. Treatment and clinical management are difficult in the relapsed/refractory (R/R) setting. Chimeric antigen receptor (CAR) T cells are genetically engineered using autologous patient lymphocytes a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2019-09-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Subjects: | |
| Online Access: | https://onco-hema.healthbooktimes.org/article/24395-cd19-directed-car-t-cells-treatment-in-a-patient-with-refractory-dlbcl-and-cns-involvement |
| _version_ | 1831704518565298176 |
|---|---|
| author | Antonia Maria S. Müller Alexander Ring |
| author_facet | Antonia Maria S. Müller Alexander Ring |
| author_sort | Antonia Maria S. Müller |
| collection | DOAJ |
| description | Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common neoplasm of the lymphatic system. Treatment and clinical management are difficult in the relapsed/refractory (R/R) setting. Chimeric antigen receptor (CAR) T cells are genetically engineered using autologous patient lymphocytes and have shown very promising results in the treatment of relapsed and refractory cases of DLBCL.
Methods
A 64-year-old male patient with refractory DLBCL and central nervous system (CNS) involvement after 9 lines of therapy was treated with CD19-specific CAR T cell therapy at the Department of medical oncology and hematology at the University Hospital of Zurich and followed-up for 10 weeks.
Results
Autologous lymphocytes were successfully harvested and transfected/expanded for CAR T cell production. Conditioning chemotherapy and CAR T infusion was well tolerated. Post-infusion side effects were mild (cytokine release syndrome [CRS] grade 1–2), with limited signs of neurotoxicity. Ten weeks after CAR T cell therapy, an excellent response could be documented via PET-CT. The CNS lesion disappeared as assessed via cranial MRI.
Conclusion
CD19-targeted CAR T cell therapy is a revolutionary treatment option for heavily pretreated R/R DLBCL even in the setting of CNS involvement. |
| first_indexed | 2024-12-20T16:00:40Z |
| format | Article |
| id | doaj.art-0edd2761479c45aab7118e8bc5e85c6d |
| institution | Directory Open Access Journal |
| issn | 2673-2092 2673-2106 |
| language | English |
| last_indexed | 2024-12-20T16:00:40Z |
| publishDate | 2019-09-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj.art-0edd2761479c45aab7118e8bc5e85c6d2022-12-21T19:34:18ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-20922673-21062019-09-01111621doi:10.36000/hbT.OH.2019.01.005CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS InvolvementAntonia Maria S. Müller0Alexander Ring1Center of Hematology and Oncology University Hospital Zurich, Zurich, SwitzerlandCenter of Hematology and Oncology University Hospital Zurich, Zurich, SwitzerlandIntroduction Diffuse large B-cell lymphoma (DLBCL) is the most common neoplasm of the lymphatic system. Treatment and clinical management are difficult in the relapsed/refractory (R/R) setting. Chimeric antigen receptor (CAR) T cells are genetically engineered using autologous patient lymphocytes and have shown very promising results in the treatment of relapsed and refractory cases of DLBCL. Methods A 64-year-old male patient with refractory DLBCL and central nervous system (CNS) involvement after 9 lines of therapy was treated with CD19-specific CAR T cell therapy at the Department of medical oncology and hematology at the University Hospital of Zurich and followed-up for 10 weeks. Results Autologous lymphocytes were successfully harvested and transfected/expanded for CAR T cell production. Conditioning chemotherapy and CAR T infusion was well tolerated. Post-infusion side effects were mild (cytokine release syndrome [CRS] grade 1–2), with limited signs of neurotoxicity. Ten weeks after CAR T cell therapy, an excellent response could be documented via PET-CT. The CNS lesion disappeared as assessed via cranial MRI. Conclusion CD19-targeted CAR T cell therapy is a revolutionary treatment option for heavily pretreated R/R DLBCL even in the setting of CNS involvement.https://onco-hema.healthbooktimes.org/article/24395-cd19-directed-car-t-cells-treatment-in-a-patient-with-refractory-dlbcl-and-cns-involvementcnscd19lymphomacar t cellsdlbcl |
| spellingShingle | Antonia Maria S. Müller Alexander Ring CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement healthbook TIMES. Oncology Hematology cns cd19 lymphoma car t cells dlbcl |
| title | CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement |
| title_full | CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement |
| title_fullStr | CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement |
| title_full_unstemmed | CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement |
| title_short | CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement |
| title_sort | cd19 directed car t cells treatment in a patient with refractory dlbcl and cns involvement |
| topic | cns cd19 lymphoma car t cells dlbcl |
| url | https://onco-hema.healthbooktimes.org/article/24395-cd19-directed-car-t-cells-treatment-in-a-patient-with-refractory-dlbcl-and-cns-involvement |
| work_keys_str_mv | AT antoniamariasmuller cd19directedcartcellstreatmentinapatientwithrefractorydlbclandcnsinvolvement AT alexanderring cd19directedcartcellstreatmentinapatientwithrefractorydlbclandcnsinvolvement |